Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 8;25(1):569.
doi: 10.1186/s12876-025-04164-8.

Epidemiologic and clinical profiles of colorectal cancer in Southern Egypt

Doris W Chiu  1 , Noha Rashad  2   3 , Nashwa Kordy  2 , Emad Shash  4   5 , Amr Soliman  6
Affiliations

Epidemiologic and clinical profiles of colorectal cancer in Southern Egypt

Doris W Chiu et al. BMC Gastroenterol. .

Abstract

Purpose: To calculate the incidence of colorectal cancer in Southern Egypt and to describe the epidemiological profiles of people with colorectal cancer in this region.

Introduction: Colorectal cancer (CRC) is one of the common cancers in high income countries but historically CRC has been uncommon in low- and middle-income countries (LMICs). Egypt was among the first countries to report higher incidence of early-onset CRC under age 40. While previous studies on CRC in Egypt over the past 3 decades have focused on Cairo and the northern Nile delta regions, this study focused on CRC in the Southern Egypt, an underserved region with distinct socioeconomic and patient constitutional characteristics.

Methods: We identified 613 CRC patients who received care during 2018-2022 at the Shefa Al-Orman Cancer Hospital (SOH), the main cancer hospital in the Luxor province in Southern Egypt. Data retrieved from the medical records included demographic, clinical, and family history of all patients managed at SOH. We calculated the incidence by two age groups, under age 45 vs. 45 + years, the incidence rate (IR), age- and sex-specific rates, and distribution of clinical characteristics.

Results: Twenty-three percent of patients were diagnosed under age 45. The 5-year incidence was 4.5 per 100,000, and the incidence rate (IR) of early-onset was 1.3 vs 18.3 per 100,000 for those 45 + years. Distant metastasis was identified in 28% of patients, and 38% of patients had rectal cancers and 58% of the patients were alive at last follow-up.

Conclusion: The incidence of early-onset and late-onset CRC is lower in Southern Egypt than the reported incidence from other regions of the country. Future etiologic studies should focus on investigating the socioeconomic and lifestyle factors of Southern Egypt. Clinical studies should also explore factors related to late-stage presentation and low survival in this population. The study may have global implications for the etiology and management of colorectal cancer.

Keywords: Colon; Colorectal cancer; Early-onset; Egypt; Population-based; Rectum.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Institutional Review Board approvals were obtained from CUNY Graduate School of Public Health and Policy and from Shefaa Al-Orman Hospital. The Shefa Al Orman Hospital -IRB is officially registered with the Supreme Council of Clinical Research Ethics (SCCRE) under the registration number SCCREIRB_SHEFAORMAN_NPO_001_020125_007. The Shefa Al Orman Hospital IRB waived the requirement of consent to participate. This study adhered to the Declaration of Helsinki and complied with the Declaration regarding human data and material. Consent for publication: Not applicable. Advisory boards/consultancy/speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Clinart MENA, Genomics Genetics, GSK, Hikma, EVA Pharma, Janssen, Lilly, MSD, Mundipharma, Newbridge Pharmaceutical, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz. Travel grants: Boehringer Ingelheim, Hikma, Janssen, Lilly, MSD, Mundipharma, Novartis, Pfizer, Roche. Clinical trials involvement: AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Roche. Competing interests: Dr. Emad Shash Advisory Boards/Consultancy/Speaker’s Bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Clinart MENA, Genomics Genetics, GSK, Hikma, EVA Pharma, Janssen, Lilly, MSD, Mundipharma, Newbridge Pharmaceutical, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz Travel Grants: Boehringer Ingelheim, Hikma, Janssen, Lilly, MSD, Mundipharma, Novartis, Pfizer, Roche Clinical Trials Involvement: AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Roche. All other authors have no conflicts of interest to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Partial map of Egypt showing the catchment area for this Southern Egyptian study population
See this image and copyright information in PMC

References

    1. Global Burden of Disease Cancer, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420–44. - PMC - PubMed
    1. A. C. Society. "Key Statistics for Colorectal Cancer." https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statis.... Accessed 2023.
    1. Soliman AS, et al. Colorectal cancer in Egyptian patients under 40 years of age. Int J Cancer. 1997;71(1):26–30. 10.1002/(sici)1097-0215(19970328)71:1%3c26::Aid-ijc6%3e3.0.Co;2-5. - PubMed
    1. Soliman AS, et al. Familial aggregation of colorectal cancer in Egypt. Int J Cancer. 1998;77(6):811–6. 10.1002/(sici)1097-0215(19980911)77:6%3c811::aid-ijc1%3e3.0.co;2-x. (in Eng). - PubMed
    1. Soliman AS, Bondy ML, Raouf AA, Makram MA, Johnston DA, Levin B. Cancer mortality in Menofeia, Egypt: comparison with US mortality rates. Cancer Causes Control. 1999;10(5):349–54. 10.1023/a:1008968701313. (in Eng). - PubMed

LinkOut - more resources